HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity.

Fiche publication

Date publication

mai 2024

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BERTAUT Aurélie , Dr BOIDOT Romain , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr CHARON-BARRA Céline

Tous les auteurs :
André C, Bertaut A, Ladoire S, Desmoulins I, Jankowski C, Beltjens F, Charon-Barra C, Bergeron A, Richard C, Boidot R, Arnould L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38893129

Résumé

With the development of some new antibody-drug conjugates, the HER2 classification of breast carcinomas now includes the HER2-low (H2L) category: IHC 1+, 2+ non-amplified by ISH, and double-equivocal carcinomas, mostly luminal, expressing hormone receptors (HR+).